Hodgkin Lymphoma   

What about if the patient has mediastinal disease and ISRT is not an option?

DLCO 65% that is of unclear etiology but not due to disease and no cardiac or pulmonary functional limitations.

Given nationwide shortage in vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...

What agents would have sufficient efficacy overlap to treat both?

How does your treatment approach vary depending on the underlying predisposition?

Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...

Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients  

Are there other regimens you employ for patients unsuitable for standard chemotherapy?

The current NCCN guideline version 2.2021 is a little confusing. On page HODG-2,  the clinical staging/risk classification did not include ESR, b...

Have the RAPID or CALGB 5064 studies changed your treatment approach?

NCCN recommends either ISRT with rituximab/chemotherapy or ISRT alone in this scenario.  What factors help your decision making?

There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.

There are multiple regimens including IGEV and most recently reported results of BEGEV without preference on NCCN guidelines.

Would you still proceed to high-dose therapy and autologous SCT? Would you incorporate radiation pre- or post- transplant? Or offer additional salvag...

Although not approved, for example, are you every using AVD-nivolumab?

Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?